On this episode of StartUp Health NOW, we’re talking with Jo Bhakdi, CEO & Founder of Quantgene, a company that joined StartUp Health in 2019. Bhakdi and his team have made a name for themselves by offering a kind of deep genomic profiling that allows them to identify cancers early, detect hereditary diseases, and find adverse drug interactions.
The name of the game here is genomic medicine and we’re not talking about 23andMe or Ancestry.com.
As you’ll hear in the interview, Bhakdi has a revolutionary vision for where the field of genomic medicine is heading in the next five years. And he’s got a strategy for getting there. Spoiler alert: Bhakdi believes that if we can get the cost of genomic testing down – which he’s actively working on – and can scale access to genomic medicine to millions of people, that could knock cancer out of the top 10 list of leading causes of death entirely. Since cancer is currently at number two, it’s a pretty radical idea, but Bhakdi has a strong track record and a compelling market strategy through Quantgene’s new offering called Serenity.
We’ll let him explain the vision in this episode.
Funders: Become a Health Moonshot Champion
Want more content like this? You can subscribe to the podcast as well as other health innovation updates at startuphealth.com/content.
Sign up for StartUp Health Insider™ to get funding insights, news, and special updates delivered to your inbox.
Looking to break down health barriers? If you’re an entrepreneur or investor, contact us to learn how you can join our Health Equity Moonshot.
Passionate about Type 1 diabetes? If you’re an entrepreneur or investor, contact us to learn how you can join our T1D Moonshot.